Compare BGH & SMTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGH | SMTI |
|---|---|---|
| Founded | 2012 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 278.7M | 208.2M |
| IPO Year | 2011 | 2008 |
| Metric | BGH | SMTI |
|---|---|---|
| Price | $14.20 | $24.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $34.00 |
| AVG Volume (30 Days) | ★ 88.7K | 57.3K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 10.06% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | ★ $15,586,976.00 |
| Revenue This Year | N/A | $17.31 |
| Revenue Next Year | N/A | $12.48 |
| P/E Ratio | ★ N/A | $496.80 |
| Revenue Growth | N/A | ★ 32.47 |
| 52 Week Low | $13.19 | $16.05 |
| 52 Week High | $16.90 | $35.70 |
| Indicator | BGH | SMTI |
|---|---|---|
| Relative Strength Index (RSI) | 59.94 | 62.65 |
| Support Level | $13.80 | $20.47 |
| Resistance Level | $14.22 | $26.48 |
| Average True Range (ATR) | 0.15 | 1.38 |
| MACD | 0.03 | 0.21 |
| Stochastic Oscillator | 90.00 | 97.59 |
Barings Global Short Duration High Yield Fund is a diversified, closed-end management investment company. Its investment objective is to seek as high a level of current income as the Adviser determines is consistent with capital preservation. The Fund seeks capital appreciation as a secondary investment objective when consistent with its primary investment objective. Under normal market conditions, the Fund will invest at least 80% of its Managed Assets in bonds, loans and other income-producing instruments that are, at the time of purchase, rated below investment grade.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.